NEW YORK (GenomeWeb) – Response Genetics today reported that its second quarter revenues declined 23 percent year over year, but were up 10 percent on a sequential basis.

The Los Angeles-based molecular diagnostics firm brought in total revenues of $4.3 million for the three months ended June 30, down from $5.3 million for the second quarter of 2013. The company said that the decline was due to pharmaceutical client revenue, which varies quarter to quarter. In addition, last year's Q2 included a $500,000 milestone payment from GlaxoSmithKline.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The World Health Organization calls for the public release of clinical trial results within a year of the completion of data collection.

In Science this week: measles virus nucleocapsid structure, and more.

African and US health officials work to establish an Africa-wide Centres for Disease Control and Prevention.

Nature has retracted a 2002 epigenetics paper for image manipulation.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.